During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Genmab A/S(Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody ...

CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...

Copenhagen-based biotech firm Genmab A/S disclosed today that Johnson & Johnson will not advance the HexaBody-CD38 program, as detailed in a recent SEC filing. The announcement was made in a Form ...

COPENHAGEN - Genmab A/S (NASDAQ:GMAB) revealed Monday that Johnson & Johnson (J&J) will not pursue the option to license HexaBody-CD38 (GEN3014) for development and commercialization. Despite ...

Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

The global Dental Implants and Prosthetics Market, valued at US$11.61 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$12.57 billion in 2025 and an impressive US$18.79 ...

Our opinions are our own. A low interest credit card saves you money by reducing the cost of debt: When you're paying less in interest, you can pay back what you've borrowed more quickly.

When it comes to commitments to growing the no-and-low category within their own portfolios, not all brewing and distilling heavyweights have established clear targets around sales or volumes. While ...